One Drop Blood Glucose Monitoring System
AgaMatrix, Inc. • Clinical Chemistry • 11/30/2016
Device Purpose
The One Drop Blood Glucose Monitoring System enables individuals with diabetes to quantitatively measure their blood glucose levels at home using fresh capillary blood from the fingertip. The system employs an electrochemical method where glucose oxidase on a test strip reacts with blood glucose to produce an electrical current proportional to the glucose concentration, which is then measured by the meter.
Summary
The One Drop Blood Glucose Monitoring System is designed for the quantitative measurement of blood glucose levels in fresh capillary whole blood samples drawn from the fingertip. It is intended for single-patient, self-testing use by individuals with diabetes at home as an aid to monitor the effectiveness of their diabetes control, and is not for diagnosis, screening, or neonatal use. The system comprises a meter, test strips, a lancing device, and lancets, among other accessories. The device operates by reacting blood on a test strip with chemicals, utilizing the enzyme glucose oxidase. This reaction generates an electrical current proportional to the blood glucose concentration, which is then measured by the meter using dynamic electrochemistry. Key characteristics include a 0.5 µL sample volume, a 5-second average test time, a measurement range of 20-600 mg/dL, and results displayed in mg/dL. The system employs non-coding test strips and can connect via Bluetooth to smart devices.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the device's performance vary across the claimed hematocrit range of 20-60%, particularly at the extremes?; What specific chemical interferences (e.g., common medications, endogenous substances) have been tested, and what are their effects on accuracy?; What is the documented precision (e.g., CV%) of the system across different glucose concentrations, as tested by lay users?; How does the system's accuracy compare to a laboratory reference method at clinically significantly high and low glucose levels?; What is the shelf-life and stability of the test strips under various storage conditions (e.g., temperature, humidity) once the vial is opened?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, ML-BOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly